CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

BACKGROUND: Locally advanced breast cancer often undergoes neoadjuvant chemotherapy (NAC), which allows in vivo evaluation of the therapeutic response. The determination of the pathological complete response (pCR) is one way to evaluate the response to neoadjuvant chemotherapy. However, the rate of...

Descripción completa

Detalles Bibliográficos
Autores principales: Alves, Wilson Eduardo Furlan Matos, Bonatelli, Murilo, Dufloth, Rozany, Kerr, Lígia Maria, Carrara, Guilherme Freire Angotti, da Costa, Ricardo Filipe Alves, Scapulatempo-Neto, Cristovam, Tiezzi, Daniel, da Costa Vieira, René Aloísio, Pinheiro, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889185/
https://www.ncbi.nlm.nih.gov/pubmed/31795962
http://dx.doi.org/10.1186/s12885-019-6353-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889185/
https://www.ncbi.nlm.nih.gov/pubmed/31795962
http://dx.doi.org/10.1186/s12885-019-6353-2

Ejemplares similares